Ketanserin: A new perspective in posttransplant erythrocytosis?

Clinical Transplantation

Volumn 10, Issue 1 I, 1996, Pages 63-66

  Borawski, Jacek ^a   Mazerska, Maria ^a   Rydzewski, Andrzej ^a   Pawlak, Krystyna ^a   Rowinski, Miroslaw ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Erythropoietin; Ketanserin; Posttransplant erythrocytosis

Indexed keywords

ERYTHROPOIETIN; KETANSERIN; SEROTONIN 2 ANTAGONIST;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; ERYTHROCYTE COUNT; ERYTHROCYTOSIS; HEMODIALYSIS; HUMAN; KIDNEY ALLOGRAFT; MALE; ORAL DRUG ADMINISTRATION; PHLEBOTOMY; PRIORITY JOURNAL; RECIPIENT;

ADULT; ERYTHROPOIETIN; HUMANS; KETANSERIN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYCYTHEMIA; POSTOPERATIVE COMPLICATIONS; SEROTONIN ANTAGONISTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029963133     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. QUNIBI WY, BARRI Y, DEVOL E, AL-FURAYAH O, SHETH K, TAHER S. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991: 40: 1153.
2. GRUBER SA, SIMMONS RL, NAJARIAN JS, et al. Post-transplant erythrocytosis and the risk of thromboembolic complications: Correlation from a prospective randomized study of cyclosporine versus azathioprine-antilymphocyte globulin. Clin Transplant 1988: 2: 60.
3. SAURON C, BERTHOUX P, BERTHOUX F, et al. New insights and treatment in post-transplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc 1993: 25: 1032.
4. CAROZZI S, GRAZIA NASINI M, SALIT M, CANTALUPPI A. NOCERA A, VALENTE U. Calcium-induced modulation of erythropoiesis in polycythemic transplanted patients. Transplant Proc 1991: 23: 1309.
5. HEILMANN E, GOTTSCHALK D, GOTTSCHALK I, LISON AE. Studies in polycythemia after kidney transplantation. Clin Nephrol 1983: 20: 94.
6. DAGHER FJ, RAMOS E, ERSLEV AJ, ALONGI SV, KARMI SA, CARD J. Are the native kidneys responsible for erythrocytosis in renal transplant allorecipients? Transplantation 1979: 28: 496.
7. PANJWABI DD, SABAWI NM. WHITE AG, et al. Post-renal transplant erythrocytosis: existence of two distinct types. Clin Transplant 1990: 4: 23
8. AEBERHARD JM, SCHNEIDER PA, VALLOTON MB, KURTZ A, LESKI M. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant recipients. Transplantation 1990: 50: 1560.
9. CONLON PJ, FARRELL J, DONOHOE J, CARMODY M, WALSHE JJ. The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation 1993: 56: 217.
10. BAKRIS GI, SAUTER ER, HUSSEY JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990: 323: 86.
11. VANHOUTTE PM. Serotonin antagonists and vascular protection. Cardiovasc Drugs Ther 1990: 4 s1: 7.
12. OSSWALD H. Renal effects of adenosine and their inhibition by teophylline in dogs. Naunyn Schmiedebergs Arch Pharmacol 1975: 288: 79.
13. GARVIN PJ, REESE JC, LINDSEY L, ARIDGE DL, DOMOTO DT, BALLAL S. Bilateral nephrectomy for posttransplant erythrocytosis - indications and results. Clin Transplant 1991: 5: 313.
14. GASTON RS, JULIAN BA, CURTIS JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994: 24: 1.
15. NAVIS G, DE JONG PE, VAN DER HEM GK, DE ZEEUW D. Renal effects of ketanserin in essential hypertension. J Hypertension 1986: 4: 95.
16. FAGARD R, FIOCCHI R, LIJNEN P, et al. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 1984: 51: 149.
17. DECREE J, GEUKENS H, LEEMPOELS J, DEMOEN B, ROELS V, VERHAEGEN H. The effects of ketanserin on the impaired blood cell filtration m patients with acute myocardial infarction. Clin Haemorrhol 1985: 5: 949.
18. KONISHI M, SAKAKURA M, TSUSHIMA N. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension. Cardiovasc Drugs Ther 1990: 4 s1: 101.
19. ECKARDT K-U, KURTZ A, BAUER C. Regulation of erythropoietin formation is related to proximal tubular function. Am J Physiol 1989: 256: F924.
20. VOROBIOFF J, GARCIA-TSAO G, GROSZMANN R, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertension. Hepatology 1989: 9: 88.
21. HADENGUE A, LEE S, MOREAU R, BRAILLON A, LEBREC D. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: Possible role of serotonergic mechanisms in portal hypertension. Hepatology 1987: 7: 644.